XML 35 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
4 Months Ended 8 Months Ended 12 Months Ended
Apr. 30, 2022
Dec. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure              
Pay vs Performance Disclosure, Table    
PAY VERSUS PERFORMANCE
The following table sets forth the compensation for our Principal Executive Officers (the “PEOs”) and the average compensation for our other named executive officers, both as reported in the Summary Compensation Table and with certain adjustments to reflect the “compensation actually paid” to such individuals, as defined under SEC rules, for each of 2024, 2023, 2022, 2021 and 2020. The table also provides information on our cumulative total shareholder return (“TSR”), the cumulative TSR of our peer group, Net Income and Adjusted EBITDA (non-GAAP) as used for our 2024, 2023, 2022, 2021 and 2020 AIP.
 
​​
Value of Initial Fixed $100
Investment Based On:​
 
 
Thomas J. Appio
Joseph C. Papa
​ Average
Summary
Compensation
Table Total
for Non-PEO
Named
Executive
Officers(1)
($)
Average
Compensation
Actually Paid
to Non-PEO
Named
Executive
Officers(2)
($) ​
Total
Shareholder
Return(3)
($)
Peer Group
Total
Shareholder
Return(3)
($)
Net
(Loss) Income
(in Millions)(4)
($)
Adjusted
EBITDA for
AIP
(in Millions)(5)
($)
Year
Summary
Compensation
Table Total
for PEO(1)
($)
Compensation
Actually
Paid to PEO(2)
($)
Summary
Compensation
Table Total for
PEO(1)
($)
Compensation
Actually Paid to
PEO(2)
($)
2024
16,239,133
19,173,285
​3,050,280
​3,710,139
27
118
(46)
2,616
2023
​15,878,578
14,834,961
2,843,374
1,029,672
27
119
(592)
2,367
2022
​13,171,461
821,019
19,781,761
(3,950,168)
5,683,018
2,050,535
21
114
(225)
2,236
2021
​—
​—
22,889,137
37,122,606
5,972,466
7,337,740
92
126
(948)
3,501
2020
​—
14,119,361
(10,609,802)
4,287,738
61,287
70
126
(560)
3,269
(1)
Compensation for our PEOs reflects the amounts reported in the “Summary Compensation Table” for the respective years. Our PEOs were (i) in 2024 and 2023, Thomas J. Appio; (ii) in 2022, Thomas J. Appio and Joseph C. Papa and (ii) in 2021 and 2020, Joseph C. Papa. Average compensation for non-PEOs includes the following named executive officers: (i) in 2024 Jean-Jacques Charhon, Seana Carson, Aimee J. Lenar and John S. Barresi, (ii) in 2023, John S. Barresi, Seana Carson and Tom G. Vadaketh, (iii) in 2022, Tom G. Vadaketh, Seana Carson, Robert A. Spurr, Sam A. Eldessouky and Christina Ackermann, (iv) in 2021, Thomas J. Appio, Robert A. Spurr, Sam A. Eldessouky, Christina M. Ackermann, and Paul S. Herendeen and (v) in 2020, Thomas J. Appio, Paul S. Herendeen, Christina M. Ackermann, and William D. Humphries.
(2)
Compensation “actually paid” for the PEO and average compensation “actually paid” for our other NEOs in 2024 reflects adjustments to the amounts in the “Summary Compensation Table” as follows in the table below, as determined in accordance with SEC rules. These dollar amounts do not reflect the actual amount of compensation earned by or paid to the PEOs and our other NEOs during the applicable year. A significant portion of the compensation “actually paid” to our NEOs is comprised of equity awards whose value is directly tied to the value of our Common Shares. For certain of the years covered by the Pay Versus Performance Table, the compensation “actually paid” to our PEO and our other NEOs was below zero as a result of the decrease in the price of our Common Shares and associated decreases in the fair value of unvested equity awards during the year. For information regarding the decisions made by the Talent and Compensation Committee for the PEO’s and our other NEOs’ compensation for fiscal year 2024, see the Compensation Discussion and Analysis beginning on page 40. Fair values set forth in the table below are computed in accordance with ASC 718 as of the end of the respective fiscal year, other than fair values of awards that vest or forfeit in the covered year, which are valued as of the applicable vesting dates and fair values as of the end of the preceding fiscal year, respectively. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant other than the expected term and the related expected volatilities and risk-free rates that have been adjusted to reflect the passage of time.
Thomas J.
Appio
2024
($)
Non-PEOs
2024
($)
Summary Compensation Table Total
16,239,133
3,050,280
Less Stock Award Value Reported in Summary Compensation Table for the Covered Year
13,141,574
2,135,326
Plus Fair Value for Awards Granted in the Covered Year
13,377,863
2,763,144
Change in Fair Value of Outstanding Unvested Awards from Prior Years
2,358,137
76,351
Change in Fair Value of Awards from Prior Years that Vested in the Covered Year
339,726
(44,310)
Less Fair Value of Awards Forfeited during the Covered Year
Plus Fair Value of Incremental Dividends or Earnings Paid on Stock Awards
Less Aggregate Change in Actuarial Present Value of Accumulated Benefit Under Pension Plans
Plus Aggregate Service Cost and Prior Service Cost for Pension Plans
Compensation Actually Paid
19,173,285
​3,710,139
(3)
TSR is cumulative for the measurement periods beginning on December 31, 2019 and ending on December 31 of each of 2024, 2023, 2022, 2021 and 2020, respectively, calculated in accordance with Item 201(e) of Regulation S-K. The peer group for purposes of this table is the Nasdaq Biotechnology Index, which is the same peer group we use for purposes of the Shareholder Return Performance Presentation of the Company’s Annual Reports on Form 10-K for the years ended December 31, 2024.
(4)
Reflects “Net Income” attributable to Bausch Health Companies Inc., as reported in the Consolidated Financial Statements included in the Company’s Annual Reports on Form 10-K for the years ended December 31, 2024, 2023, 2022, 2021 and 2020 (including net income attributable to noncontrolling interests).
(5)
Reflects Adjusted EBITDA as used for our AIP in 2024, 2023, 2022, 2021 and 2020. Adjusted EBITDA as used for the AIP in 2020 and 2021 was calculated on a consolidated basis, for the AIP in 2022 AIP, Adjusted EBITDA does not include Adjusted EBITDA attributable to B+L or our Solta Medical business, for the 2024 and 2023 AIP Adjusted EBITDA does not include Adjusted EBITDA attributable to B+L. Adjusted EBITDA is a non-GAAP financial measure that may not be comparable to similar measures used by other companies. Please see Appendix 1 for a reconciliation of our GAAP to non-GAAP financial measures and related disclosures.
       
Company Selected Measure Name     Adjusted EBITDA        
Named Executive Officers, Footnote    
(1)
Compensation for our PEOs reflects the amounts reported in the “Summary Compensation Table” for the respective years. Our PEOs were (i) in 2024 and 2023, Thomas J. Appio; (ii) in 2022, Thomas J. Appio and Joseph C. Papa and (ii) in 2021 and 2020, Joseph C. Papa. Average compensation for non-PEOs includes the following named executive officers: (i) in 2024 Jean-Jacques Charhon, Seana Carson, Aimee J. Lenar and John S. Barresi, (ii) in 2023, John S. Barresi, Seana Carson and Tom G. Vadaketh, (iii) in 2022, Tom G. Vadaketh, Seana Carson, Robert A. Spurr, Sam A. Eldessouky and Christina Ackermann, (iv) in 2021, Thomas J. Appio, Robert A. Spurr, Sam A. Eldessouky, Christina M. Ackermann, and Paul S. Herendeen and (v) in 2020, Thomas J. Appio, Paul S. Herendeen, Christina M. Ackermann, and William D. Humphries.
       
Peer Group Issuers, Footnote    
(3)
TSR is cumulative for the measurement periods beginning on December 31, 2019 and ending on December 31 of each of 2024, 2023, 2022, 2021 and 2020, respectively, calculated in accordance with Item 201(e) of Regulation S-K. The peer group for purposes of this table is the Nasdaq Biotechnology Index, which is the same peer group we use for purposes of the Shareholder Return Performance Presentation of the Company’s Annual Reports on Form 10-K for the years ended December 31, 2024.
       
Adjustment To PEO Compensation, Footnote    
(2)
Compensation “actually paid” for the PEO and average compensation “actually paid” for our other NEOs in 2024 reflects adjustments to the amounts in the “Summary Compensation Table” as follows in the table below, as determined in accordance with SEC rules. These dollar amounts do not reflect the actual amount of compensation earned by or paid to the PEOs and our other NEOs during the applicable year. A significant portion of the compensation “actually paid” to our NEOs is comprised of equity awards whose value is directly tied to the value of our Common Shares. For certain of the years covered by the Pay Versus Performance Table, the compensation “actually paid” to our PEO and our other NEOs was below zero as a result of the decrease in the price of our Common Shares and associated decreases in the fair value of unvested equity awards during the year. For information regarding the decisions made by the Talent and Compensation Committee for the PEO’s and our other NEOs’ compensation for fiscal year 2024, see the Compensation Discussion and Analysis beginning on page 40. Fair values set forth in the table below are computed in accordance with ASC 718 as of the end of the respective fiscal year, other than fair values of awards that vest or forfeit in the covered year, which are valued as of the applicable vesting dates and fair values as of the end of the preceding fiscal year, respectively. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant other than the expected term and the related expected volatilities and risk-free rates that have been adjusted to reflect the passage of time.
Thomas J.
Appio
2024
($)
Non-PEOs
2024
($)
Summary Compensation Table Total
16,239,133
3,050,280
Less Stock Award Value Reported in Summary Compensation Table for the Covered Year
13,141,574
2,135,326
Plus Fair Value for Awards Granted in the Covered Year
13,377,863
2,763,144
Change in Fair Value of Outstanding Unvested Awards from Prior Years
2,358,137
76,351
Change in Fair Value of Awards from Prior Years that Vested in the Covered Year
339,726
(44,310)
Less Fair Value of Awards Forfeited during the Covered Year
Plus Fair Value of Incremental Dividends or Earnings Paid on Stock Awards
Less Aggregate Change in Actuarial Present Value of Accumulated Benefit Under Pension Plans
Plus Aggregate Service Cost and Prior Service Cost for Pension Plans
Compensation Actually Paid
19,173,285
​3,710,139
       
Non-PEO NEO Average Total Compensation Amount     $ 3,050,280 $ 2,843,374 $ 5,683,018 $ 5,972,466 $ 4,287,738
Non-PEO NEO Average Compensation Actually Paid Amount     $ 3,710,139 1,029,672 2,050,535 7,337,740 61,287
Adjustment to Non-PEO NEO Compensation Footnote    
(2)
Compensation “actually paid” for the PEO and average compensation “actually paid” for our other NEOs in 2024 reflects adjustments to the amounts in the “Summary Compensation Table” as follows in the table below, as determined in accordance with SEC rules. These dollar amounts do not reflect the actual amount of compensation earned by or paid to the PEOs and our other NEOs during the applicable year. A significant portion of the compensation “actually paid” to our NEOs is comprised of equity awards whose value is directly tied to the value of our Common Shares. For certain of the years covered by the Pay Versus Performance Table, the compensation “actually paid” to our PEO and our other NEOs was below zero as a result of the decrease in the price of our Common Shares and associated decreases in the fair value of unvested equity awards during the year. For information regarding the decisions made by the Talent and Compensation Committee for the PEO’s and our other NEOs’ compensation for fiscal year 2024, see the Compensation Discussion and Analysis beginning on page 40. Fair values set forth in the table below are computed in accordance with ASC 718 as of the end of the respective fiscal year, other than fair values of awards that vest or forfeit in the covered year, which are valued as of the applicable vesting dates and fair values as of the end of the preceding fiscal year, respectively. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant other than the expected term and the related expected volatilities and risk-free rates that have been adjusted to reflect the passage of time.
Thomas J.
Appio
2024
($)
Non-PEOs
2024
($)
Summary Compensation Table Total
16,239,133
3,050,280
Less Stock Award Value Reported in Summary Compensation Table for the Covered Year
13,141,574
2,135,326
Plus Fair Value for Awards Granted in the Covered Year
13,377,863
2,763,144
Change in Fair Value of Outstanding Unvested Awards from Prior Years
2,358,137
76,351
Change in Fair Value of Awards from Prior Years that Vested in the Covered Year
339,726
(44,310)
Less Fair Value of Awards Forfeited during the Covered Year
Plus Fair Value of Incremental Dividends or Earnings Paid on Stock Awards
Less Aggregate Change in Actuarial Present Value of Accumulated Benefit Under Pension Plans
Plus Aggregate Service Cost and Prior Service Cost for Pension Plans
Compensation Actually Paid
19,173,285
​3,710,139
       
Equity Valuation Assumption Difference, Footnote    
(2)
Compensation “actually paid” for the PEO and average compensation “actually paid” for our other NEOs in 2024 reflects adjustments to the amounts in the “Summary Compensation Table” as follows in the table below, as determined in accordance with SEC rules. These dollar amounts do not reflect the actual amount of compensation earned by or paid to the PEOs and our other NEOs during the applicable year. A significant portion of the compensation “actually paid” to our NEOs is comprised of equity awards whose value is directly tied to the value of our Common Shares. For certain of the years covered by the Pay Versus Performance Table, the compensation “actually paid” to our PEO and our other NEOs was below zero as a result of the decrease in the price of our Common Shares and associated decreases in the fair value of unvested equity awards during the year. For information regarding the decisions made by the Talent and Compensation Committee for the PEO’s and our other NEOs’ compensation for fiscal year 2024, see the Compensation Discussion and Analysis beginning on page 40. Fair values set forth in the table below are computed in accordance with ASC 718 as of the end of the respective fiscal year, other than fair values of awards that vest or forfeit in the covered year, which are valued as of the applicable vesting dates and fair values as of the end of the preceding fiscal year, respectively. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant other than the expected term and the related expected volatilities and risk-free rates that have been adjusted to reflect the passage of time.
       
Compensation Actually Paid vs. Total Shareholder Return    
Compensation Actually Paid and Cumulative TSR of the Company and Cumulative TSR of the Peer Group
The graph below shows how the amount of compensation actually paid to our PEOs and the average amount of compensation actually paid to our other NEOs compared with the Company’s TSR over the covered fiscal years. The following performance graph also compares the cumulative total return on a $100 investment on December 31, 2019, assuming reinvestment of all dividends, in (i) our Common Shares and (ii) the NASDAQ Biotechnology Index.
       
Compensation Actually Paid vs. Net Income    
Compensation Actually Paid and Net (Loss) Income
The graph below reflects a comparison of compensation actually paid to our PEOs and the average amount of compensation actually paid to our other NEOs with our consolidated net (loss) income from continuing operations.
       
Compensation Actually Paid vs. Company Selected Measure    
Compensation Actually Paid and Adjusted EBITDA
The graph below shows how the amount of compensation actually paid to our PEOs and the average amount of compensation actually paid to our other NEOs compared with our Adjusted EBITDA as used for our AIP in 2024, 2023, 2022, 2021, and 2020. Adjusted EBITDA as used for our AIP for 2020 and 2021 was on a consolidated basis, for 2022, Adjusted EBITDA did not include B+L or our Solta Medical business and for 2024 and 2023 did not include B+L. Adjusted EBITDA is a non-GAAP financial measure that may not be comparable to similar measures used by other companies. Please see Appendix 1 for a reconciliation of our GAAP to non-GAAP financial measures and related disclosures
       
Total Shareholder Return Vs Peer Group    
Compensation Actually Paid and Cumulative TSR of the Company and Cumulative TSR of the Peer Group
The graph below shows how the amount of compensation actually paid to our PEOs and the average amount of compensation actually paid to our other NEOs compared with the Company’s TSR over the covered fiscal years. The following performance graph also compares the cumulative total return on a $100 investment on December 31, 2019, assuming reinvestment of all dividends, in (i) our Common Shares and (ii) the NASDAQ Biotechnology Index.
       
Tabular List, Table    
The following table sets forth an unranked list of the performance measures that, for 2024, we view as the “most important” measures for linking our NEOs’ compensation “actually paid” to performance. Revenue and Adjusted EBITDA (non-GAAP) were metrics used for our AIP in each of the years covered by the above table, as well as Adjusted Operating Cash Flow performance goal and Relative Total Shareholder Return which are used under our PSU award program.
​Performance Measure
Revenue
​Adjusted EBITDA (non-GAAP)
Adjusted Operating Cash Flow (non-GAAP)
​rTSR (Relative Total Shareholder Return)
       
Total Shareholder Return Amount     $ 27 27 21 92 70
Peer Group Total Shareholder Return Amount     118 119 114 126 126
Net Income (Loss)     $ (46,000,000) $ (592,000,000) $ (225,000,000) $ (948,000,000) $ (560,000,000)
Company Selected Measure Amount     2,616,000,000 2,367,000,000 2,236,000,000 3,501,000,000 3,269,000,000
PEO Name Joseph C. Papa Thomas J. Appio Thomas J. Appio Thomas J. Appio   Joseph C. Papa Joseph C. Papa
Measure:: 1              
Pay vs Performance Disclosure              
Name     Revenue        
Measure:: 2              
Pay vs Performance Disclosure              
Name     Adjusted EBITDA (non-GAAP)        
Non-GAAP Measure Description    
(5)
Reflects Adjusted EBITDA as used for our AIP in 2024, 2023, 2022, 2021 and 2020. Adjusted EBITDA as used for the AIP in 2020 and 2021 was calculated on a consolidated basis, for the AIP in 2022 AIP, Adjusted EBITDA does not include Adjusted EBITDA attributable to B+L or our Solta Medical business, for the 2024 and 2023 AIP Adjusted EBITDA does not include Adjusted EBITDA attributable to B+L. Adjusted EBITDA is a non-GAAP financial measure that may not be comparable to similar measures used by other companies. Please see Appendix 1 for a reconciliation of our GAAP to non-GAAP financial measures and related disclosures.
       
Measure:: 3              
Pay vs Performance Disclosure              
Name     Adjusted Operating Cash Flow (non-GAAP)        
Measure:: 4              
Pay vs Performance Disclosure              
Name     rTSR (Relative Total Shareholder Return)        
Thomas J. Appio [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount     $ 16,239,133 $ 15,878,578 $ 13,171,461 $ 0 $ 0
PEO Actually Paid Compensation Amount     19,173,285 14,834,961 821,019 0 0
Joseph C. Papa [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount     0 0 19,781,761 22,889,137 14,119,361
PEO Actually Paid Compensation Amount     0 $ 0 $ (3,950,168) $ 37,122,606 $ (10,609,802)
PEO | Thomas J. Appio [Member] | Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Thomas J. Appio [Member] | Aggregate Pension Adjustments Service Cost              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Thomas J. Appio [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (13,141,574)        
PEO | Thomas J. Appio [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     13,377,863        
PEO | Thomas J. Appio [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     2,358,137        
PEO | Thomas J. Appio [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     339,726        
PEO | Thomas J. Appio [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Thomas J. Appio [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
Non-PEO NEO | Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
Non-PEO NEO | Aggregate Pension Adjustments Service Cost              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (2,135,326)        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     2,763,144        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     76,351        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (44,310)        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     $ 0